Rondo Therapeutics Releases Data on RNDO-564 for Bladder Cancer
08 Apr 2025 //
BUSINESSWIRE
Rondo Therapeutics Presents Preclinical Data in Bladder Cancer
10 Feb 2025 //
BUSINESSWIRE
Thomas Manley, M.D. Joins Rondo Therapeutics as CMO
19 Nov 2024 //
BUSINESSWIRE
Steven James Joins Rondo Therapeutics Board Of Directors
02 Jul 2024 //
BUSINESSWIRE